Clinical trials: Metabolic Testing
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Adults With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0941-018)
The purpose of this study is to test the effect MK-0941 as add-on therapy for adults taking insulin for Type 2 Diabetes.
- Trial name
- NCT00824616
- Testing
- MK-0941, Insulin
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
Glucose Meter Study
The purpose of this study is to evaluate if the meal marker and reminder feature of the Contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that…
- Trial name
- NCT00782496
- Testing
- Education + new meter, Education + new meter + feature activation
- Where
- 4 sites in United States
- Volunteers
- 211 people
- Sponsor
- Ascensia Diabetes Care
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Phenylketonuria
Response to Kuvan® in Subjects With Phenylketonuria (PKU) in a 4 Weeks Testing Period
The primary objective of the study is to evaluate the proportion of responders (that is, greater than or equal to [>=] 30 percent reduction from Baseline in blood phenylalanine [Phe] level) to treatment with Kuvan® (sapropterin…
- Trial name
- ENDURE (NCT01082328)
- Testing
- Kuvan®
- Where
- Norway
- Volunteers
- 59 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy
Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
- Trial name
- NCT01819922
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
- Trial name
- NCT05258110
- Testing
- midazolam, iclepertin (BI 425809)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of MK1006
- Trial name
- NCT00757601
- Testing
- MK1006
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
The main objectives of this trial are: To investigate basic pharmacokinetics of BI 1569912 and total radioactivity, including mass balance, excretion pathways and metabolism following oral administration of BI 1569912 (C-14) to…
- Trial name
- NCT06520553
- Testing
- BI 1569912 (C-14), BI 1569912 (C-13)
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes
Glucose Control Using 1,5-AG Testing
Glycemic excursions (temporary increases in blood glucose) are associated with health complications. Standard tests for diabetes (e.g.
- Trial name
- GLUCAR (NCT03765164)
- Testing
- GlycoMark 1-5-AG, Clinical Performance and Value Vignettes
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Type 2 Diabetes Mellitus
A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking metformin for type 2 diabetes.
- Trial name
- NCT00792935
- Testing
- MK-0941, Glimepiride, Metformin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Primary objective mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1467335 given to healthy male subjects (a selected number of subjects will be treated with [14C]BI 1467335 after a…
- Trial name
- NCT03382509
- Testing
- [14C]BI 1467335, BI 1467335
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes
Test the safety, tolerability and improvement of blood sugar control with combination therapy in individuals with Type 2 Diabetes.
- Trial name
- NCT00853151
- Testing
- LY2428757, TT223
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 131 people
- Sponsor
- Eli Lilly and Company
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Diabetes Mellitus, Type 2
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar.
- Trial name
- NCT04153929
- Testing
- BI 456906, Semaglutide
- Where
- 80 sites in United States, Australia and 12 more
- Volunteers
- 413 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride.
- Trial name
- NCT00701090
- Testing
- sitagliptin, Comparator: glimepiride, open-label metformin
- Volunteers
- 1,035 people
- Sponsor
- Merck Sharp & Dohme LLC
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Diabetes Mellitus
Performance of the L-PLUS BGMS by Persons With Diabetes Mellitus
L-PLUS (Lightning PLUS) is the code name of a blood glucose monitoring system (BGMS) consisting of a new meter and marketed CONTOUR PLUS® test strip.
- Trial name
- NCT04033315
- Testing
- L-PLUS meter
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Ascensia Diabetes Care
Osteoporosis, Postmenopausal
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
- Trial name
- NCT04729621
- Testing
- TVB-009, Prolia®
- Where
- 78 sites in United States, Bulgaria and 8 more
- Volunteers
- 332 people
- Sponsor
- Teva Pharmaceuticals USA